Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines-Reference-Cited by-同舟云学术

Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines

Published:2020-05-22 Issue:9 Volume:92 Page:1495-1500
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Zheng Yunfeng¹,Li Renfeng²^ORCID,Liu Shunai³

Affiliation:

1. Beijing Aldans Biotech Company Beijing China

2. Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Philips Institute for Oral Health ResearchVirginia Commonwealth University Richmond Virginia

3. Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Institute of Infectious DiseasesCapital Medical University Beijing China

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26009

Reference48 articles.

1. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 1 May 2020.

2. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

3. Immune phenotyping based on neutrophil‐to‐lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID‐19;Zhang B;medRxiv,2020

4. Effectiveness of convalescent plasma therapy in severe COVID-19 patients

5. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study;Orphanet Journal of Rare Diseases;2024-07-03

2. Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study;BMC Nephrology;2024-04-08

3. Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks;Cell Cycle;2024-02-16

4. MTOR gene variants are associated with severe COVID-19 outcomes: A multicenter study;International Immunopharmacology;2023-12

5. Cannabinoids Receptors in COVID-19: Perpetrators and Victims;Current Medicinal Chemistry;2023-10